<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411667</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-IVIG</org_study_id>
    <secondary_id>2004902</secondary_id>
    <nct_id>NCT04411667</nct_id>
  </id_info>
  <brief_title>Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection</brief_title>
  <official_title>Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Sakoulas, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sharp HealthCare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce
      respiratory complications (respiratory failure and need for a ventilator) caused by
      coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized
      IVIG for patients infected with the influenza virus. He wants to find out if IVIG is equally
      effective in COVID-19 infection patients, and if IVIG will give the immune system some help
      to clear the infection naturally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator initiated, open label, multicenter, two arm, randomized study to
      compare the impact of adding IVIG to the Standard of Care (SOC) to the SOC without IVIG.
      Randomization will be 1:1. The goal of this study is to identify whether or not IVIG can halt
      the progression to respiratory failure requiring mechanical ventilation in subjects admitted
      to the hospital with confirmed COVID-19. The addition of IVIG to the standard of care
      treatment for these patients may be beneficial in abating acute lung injury in subjects with
      SARSCoV-2 induced hypoxia that results in organ injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized into one of two groups: Standard of Care plus IVIG or Standard of Care.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical Ventilation</measure>
    <time_frame>from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days</time_frame>
    <description>Number of subjects requiring mechanical ventilation due to respiratory failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Therapy</measure>
    <time_frame>from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days</time_frame>
    <description>Number of days requiring oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days</time_frame>
    <description>Number of days in hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Group A (study drug+SOC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (SOC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octagam</intervention_name>
    <description>Standard of Care plus Octagam infusion for 3 days.</description>
    <arm_group_label>Group A (study drug+SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed COVID-19 positive test result (including presumptive positive).

          -  Hospitalization

          -  Requiring ≥4 liters/min O2 nasal cannula to maintain oxygen saturation ≥ 92%, but not
             mechanically ventilated

          -  Age ≥18 years old.

          -  Access to a phone in the hospital room or an electronic device that is capable of
             receiving phone calls and/or video calls and/or e-mail.

          -  Able to read/write/speak English or Spanish fluently.

          -  Subjects must have the capacity to provide consent or an appropriate Legally
             Authorized Representative (LAR) to provide informed consent.

        provide informed consent, and provide authorization of use and disclosure of personal
        health information.

          -  Negative pregnancy test for women of childbearing potential.

        Exclusion Criteria:

          -  Severe allergy to any IVIG product formulation

          -  History of DVT, PE, thromboembolic stroke or other thrombotic events

          -  Hypersensitivity to corn. Octagam® contains maltose which is a sugar derived from
             corn.

          -  Uncontrolled hypertension (SBP&gt;180 mm Hg or DBP&gt;120mmHg)

          -  Active participant in another research treatment study

          -  Mechanically ventilated patient

          -  Code status is Do Not Resuscitate or Do Not Intubate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sakoulas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharp HealthCare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie Miller</last_name>
    <phone>828-939-7162</phone>
    <email>kathryn.miller@sharp.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cary Murphy, RN</last_name>
    <phone>619-740-4363</phone>
    <email>cary.murphy@sharp.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Grossmont Hospital</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cary Murphy, RN</last_name>
      <phone>619-740-4363</phone>
      <email>cary.murphy@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Valdez-Hernandez, RN</last_name>
      <phone>(619)458-2260</phone>
      <email>Adriana.Valdez-hernandez@sharp.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Geriak, PharmD</last_name>
      <phone>858-939-3717</phone>
      <email>matthew.geriak@sharp.com</email>
    </contact>
    <contact_backup>
      <last_name>Cary Murphy, RN</last_name>
      <phone>(619) 740-4363</phone>
      <email>cary.murphy@sharp.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sharp HealthCare</investigator_affiliation>
    <investigator_full_name>George Sakoulas, MD</investigator_full_name>
    <investigator_title>Infectious Disease Specialist</investigator_title>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <keyword>IVIG</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

